• Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent

• Males and females age ≥ 18 years

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 2

• Measurable disease by RECIST 1.1

• Women of childbearing potential must have a negative serum pregnancy test within one month prior to initiating treatment

• Pathologically proven diagnosis of Stage IIIA or IIIB non-small cell lung cancer (NSCLC)

• No Positron Emission Tomography (PET)/CT evidence of metastatic disease

• An MRI of the brain with contrast excluding intracranial metastatic disease (or CT with contrast if MRI is medically contraindicated). An MRI without contrast is only permitted if the subject cannot have contrast for medical reasons

• If a pleural effusion is present, it must be tapped and confirmed to be cytologically negative. If an effusion is deemed too small to safely tap, the subject will be eligible

• Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception listed in Child-Bearing Potential/Pregnancy section for the duration of study participation and for 90 days following completion of therapy

• Adequate organ function per laboratory results